CU20160072A7 - Tienopirimidinas como inhibidores mknk1 y mknk2 - Google Patents

Tienopirimidinas como inhibidores mknk1 y mknk2

Info

Publication number
CU20160072A7
CU20160072A7 CUP2016000072A CU20160072A CU20160072A7 CU 20160072 A7 CU20160072 A7 CU 20160072A7 CU P2016000072 A CUP2016000072 A CU P2016000072A CU 20160072 A CU20160072 A CU 20160072A CU 20160072 A7 CU20160072 A7 CU 20160072A7
Authority
CU
Cuba
Prior art keywords
compounds
tienopirimidins
mknk1
mknk2
inhibitors
Prior art date
Application number
CUP2016000072A
Other languages
English (en)
Inventor
Dr Ulrich Klar
Dr Lars Wortmann
Dr Georg Kettschau
Dr Keith Graham
Dr Anja Richter
Dr Philip Lienau
Dr Florian Puehler
Dr Kirstin Petersen
Dr Franziska Siegel
Dr Detlev Sülzle
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CU20160072A7 publication Critical patent/CU20160072A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

ESPACIO PARA FÓRMULA I Compuestos de tienopirimidina sustituidos de la fórmula general (I) que se describen y definen en la presente, métodos de preparación de dichos compuestos, compuestos intermediarios de utilidad para preparar dichos compuestos, composiciones y combinaciones farmacéuticas que comprenden dichos compuestos y el uso de dichos compuestos en la elaboración de una composición farmacéutica para el tratamiento o la profilaxis de una enfermedad, en particular de un trastorno hiperproliferativo y/o de angiogénesis, como agente único o en combinación con otros ingredientes activos.
CUP2016000072A 2013-11-20 2016-05-20 Tienopirimidinas como inhibidores mknk1 y mknk2 CU20160072A7 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13193665 2013-11-20
EP14174731 2014-06-27
PCT/EP2014/074722 WO2015074986A1 (en) 2013-11-20 2014-11-17 Thienopyrimidines as mknk1 and mknk2 inhibitors

Publications (1)

Publication Number Publication Date
CU20160072A7 true CU20160072A7 (es) 2016-10-28

Family

ID=52000798

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2016000072A CU20160072A7 (es) 2013-11-20 2016-05-20 Tienopirimidinas como inhibidores mknk1 y mknk2

Country Status (22)

Country Link
US (1) US20160297833A1 (es)
EP (1) EP3071577A1 (es)
JP (1) JP2016539113A (es)
KR (1) KR20160086404A (es)
CN (1) CN106061980A (es)
AP (1) AP2016009225A0 (es)
AU (1) AU2014352066A1 (es)
BR (1) BR112016011472A2 (es)
CA (1) CA2930873A1 (es)
CL (1) CL2016001218A1 (es)
CR (1) CR20160235A (es)
CU (1) CU20160072A7 (es)
DO (1) DOP2016000118A (es)
EA (1) EA201600398A1 (es)
IL (1) IL245404A0 (es)
MX (1) MX2016006631A (es)
PE (1) PE20160593A1 (es)
PH (1) PH12016500931A1 (es)
TN (1) TN2016000194A1 (es)
TW (1) TW201605867A (es)
UY (1) UY35848A (es)
WO (1) WO2015074986A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
KR20180070696A (ko) * 2015-10-29 2018-06-26 이펙터 테라퓨틱스, 인크. Mnk1 및 mnk2를 억제하는 피롤로-, 피라졸로-, 이미다조-피리미딘 및 피리딘 화합물
SG11201803242TA (en) * 2015-10-29 2018-05-30 Effector Therapeutics Inc Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of mnk1 and mnk2
WO2017087808A1 (en) 2015-11-20 2017-05-26 Effector Therapeutics, Inc. Heterocyclic compounds that inhibit the kinase activity of mnk useful for treating various cancers
CN106727587A (zh) * 2016-11-28 2017-05-31 李娜 一种治疗心律失常的药物组合物
US20190388425A1 (en) 2017-01-20 2019-12-26 Bayer Pharma Aktiengesellschaft Substituted imidazopyridinpyrimidines
WO2018152117A1 (en) 2017-02-14 2018-08-23 Effector Therapeutics, Inc. Piperidine-substituted mnk inhibitors and methods related thereto
US11130757B2 (en) 2018-10-24 2021-09-28 Effector Therapeutics Inc. Crystalline forms of MNK inhibitors
CN110981903A (zh) * 2019-11-28 2020-04-10 南京正济医药研究有限公司 一种艾日布林中间体化合物提高光学纯度的精制方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849638B2 (en) * 2001-04-30 2005-02-01 Bayer Pharmaceuticals Corporation 4-amino-5,6-substituted thiopheno [2,3-d] pyrimidines, pharmaceutical compositions containing the same, and their use in the treatment or prevention of pde7b-mediated diseases and conditions
CA2472619A1 (en) * 2002-01-10 2003-07-24 Bayer Corporation Fused pyrimidine derivates as rho-kinase inhibitors
WO2005010008A1 (en) * 2003-07-24 2005-02-03 Bayer Pharmaceuticals Corporation Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders
CA2577664A1 (en) * 2004-08-20 2006-03-02 Bayer Pharmaceuticals Corporation Novel heterocycles
UY29161A1 (es) * 2004-10-15 2006-04-28 Bayer Pharmaceuticals Corp Nuevos heterociclos
EP1899353A1 (en) * 2005-06-22 2008-03-19 DeveloGen Aktiengesellschaft Thienopyrimidines for pharmaceutical compositions
WO2007059905A2 (en) * 2005-11-25 2007-05-31 Develogen Aktiengesellschaft Thienopyrimidines treating inflammatory diseases
PH12012501693A1 (en) * 2010-02-26 2012-11-05 Boehringer Ingelheim Int 4 - [cycloalkyloxy (hetero) arylamino] thieno [2,3 - d] pyrimidines having mnkl/mnk2 inhibiting activity for pharmaceutical compositions
BR112014017021A8 (pt) * 2012-01-10 2017-07-04 Nimbus Iris Inc inibidores de irak e usos dos mesmos
ES2591129T3 (es) * 2012-05-21 2016-11-25 Bayer Pharma Aktiengesellschaft Tienopirimidinas
WO2013174743A1 (en) * 2012-05-21 2013-11-28 Bayer Pharma Aktiengesellschaft Substituted pyrrolopyrimidines
EP2852595B1 (en) * 2012-05-21 2016-06-22 Bayer Pharma Aktiengesellschaft Substituted benzothienopyrimidines
CN105189518A (zh) * 2013-02-01 2015-12-23 拜耳制药股份公司 取代的噻吩并吡啶和其药物用途
TN2016000005A1 (en) * 2013-07-08 2017-07-05 Bayer Pharma AG Substituted pyrazolo-pyridinamines

Also Published As

Publication number Publication date
CA2930873A1 (en) 2015-05-28
PH12016500931A1 (en) 2016-06-27
EP3071577A1 (en) 2016-09-28
PE20160593A1 (es) 2016-07-13
MX2016006631A (es) 2016-08-17
BR112016011472A2 (pt) 2017-09-26
US20160297833A1 (en) 2016-10-13
DOP2016000118A (es) 2016-06-30
CR20160235A (es) 2016-07-20
AU2014352066A1 (en) 2016-05-26
TN2016000194A1 (en) 2017-10-06
IL245404A0 (en) 2016-06-30
WO2015074986A1 (en) 2015-05-28
TW201605867A (zh) 2016-02-16
JP2016539113A (ja) 2016-12-15
KR20160086404A (ko) 2016-07-19
EA201600398A1 (ru) 2016-10-31
CN106061980A (zh) 2016-10-26
CL2016001218A1 (es) 2016-12-16
UY35848A (es) 2015-06-30
AP2016009225A0 (en) 2016-05-31

Similar Documents

Publication Publication Date Title
ECSP17007538A (es) 2-(morfolin-4-il)-1,7-naftiridinas
UY35040A (es) Pirrolopirimidinilamino-benzotiazolonas sustituidas
CU20160072A7 (es) Tienopirimidinas como inhibidores mknk1 y mknk2
UY33598A (es) Imidazopiridazinas sustituidas
DOP2017000137A (es) Benzamidas sustituidas con 1,3–tiazol–2–ilo.
NI201500118A (es) Imidazopiridazinas sustituidas
CO2017005968A2 (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
CR20160433A (es) Nuevos compuestos
MX348064B (es) Imidazopiridazinas sustituidas con amino.
NI201600006A (es) Pirazolo-piridinaminas sustituidas
NI201500175A (es) Compuestos nuevos para el tratamiento del cáncer
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt
UY37444A (es) Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y su uso
UY36983A (es) Pirazolopiridinaminas sustituidas
UY34630A (es) Imidazopiridazinas sustituidas con amino